Objective: The stepped wedge design is increasingly being used in cluster randomized trials (CRTs). However, there is not much information available about the design and analysis strategies for these kinds of trials. Approaches to sample size and power calculations have been provided, but a simple sample size formula is lacking. Therefore, our aim is to provide a sample size formula for cluster randomized stepped wedge designs.
Study Design And Setting: We derived a design effect (sample size correction factor) that can be used to estimate the required sample size for stepped wedge designs. Furthermore, we compared the required sample size for the stepped wedge design with a parallel group and analysis of covariance (ANCOVA) design.
Results: Our formula corrects for clustering as well as for the design. Apart from the cluster size and intracluster correlation, the design effect depends on choices of the number of steps, the number of baseline measurements, and the number of measurements between steps. The stepped wedge design requires a substantial smaller sample size than a parallel group and ANCOVA design.
Conclusion: For CRTs, the stepped wedge design is far more efficient than the parallel group and ANCOVA design in terms of sample size.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jclinepi.2013.01.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synergetic efficiency: growth of a novel 2D/2D chemically bonded BiO/CsBiBr S-scheme heterostructure for improved photocatalytic performance and stability.
Nanoscale Adv
January 2025
Department of Production Engineering, Faculty of Mechanical Engineering, University of Aleppo Aleppo Syria
Adverse reactions caused by waterborne contaminants constitute a major hazard to the environment. Controlling the pollutants released into aquatic systems through water degradation has been one of the major concerns of recent research. Bismuth-based perovskites have exhibited outstanding properties in the field of photocatalysis.
View Article and Find Full Text PDFManagement and Outcomes of Type I and Type II Myocardial Infarction in Cardiogenic Shock.
CJC Open
February 2024
CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Background: Type I myocardial infarction (T1MI) or type II myocardial infarction (T2MI) have different underlying mechanisms; however, in the setting of cardiogenic shock (CS), it is not understood if patients experience resultantly different outcomes. The objective of this study was to determine clinical features, biomarker patterns, and outcomes in these subgroups.
Methods: Patients from the CAPITAL-DOREMI trial presenting with acute myocardial infarction-associated CS (n = 103) were classified as T1MI (n = 61) or T2MI (n = 42).
Does radiofrequency ablation of the lower oesophagus allow for clonal expansion of highly mutated neosquamous epithelium?
BMJ Oncol
October 2023
Department of Pathology, University of California San Francisco, San Francisco, California, USA.
Objective: In Barrett's oesophagus (BE), after radiofrequency ablation (RFA), the oesophagus can be repopulated with a stratified 'neosquamous epithelium' (NeoSE). While histologically normal, the origin and clonal make-up of this NeoSE is unknown. An increased understanding of NeoSE is important as some studies suggest that NeoSE is biologically abnormal.
View Article and Find Full Text PDFShort-term Assessment of Glaucoma Progression in Clinical Trials Using Trend-based Visual Field Progression Analysis.
Ophthalmol Sci
November 2024
Department of Ophthalmology, National Center for Global Health and Medicine, Tokyo, Japan.
Objective: To evaluate the effect of disease stage, frequency and clustering of visual field (VF) tests, inclusion of 1 or both eyes, and 1 (1 arm; before and after a treatment) or 2 groups (2 arms; treatment and control arm) on sample size calculation in clinical trials.
Design: Clinical cohort study.
Participants: A series of VFs were simulated based on test-retest VF data in the early, moderate, and advanced stages of glaucoma with 231, 204, and 226 eyes, respectively.
Objective: Our objective of this study was to analyse all oncological clinical trials using regorafenib to create a complete risk/benefit profile for the drug.
Background: Creating a novel chemotherapy is costly both in time and capital spent for drug manufacturers. To regenerate what they've spent, drug manufacturers may attempt to repurpose their medications for new indications via clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!